GlassScriptPhysician profile
Julie Mallory
NPI 1740506575
$3,775.55
in general payments reported to CMS, 2019-2025
26 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $546 · 2022: $806 · 2023: $1,758 · 2024: $399 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,292 · Food and Beverage: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,291.79 |
| Food and Beverage | $1,131.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,827.84 | 2021-2024 | Omnia, Senza |
| Abbvie INC. | $603.32 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $446.72 | 2021-2025 | Belbuca, Xtampza |
| Biohaven Pharmaceutical Holding Company LTD. | $145.03 | 2022 | |
| Impel Pharmaceuticals INC. | $116.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $79.27 | 2021 | |
| Pfizer INC. | $65.91 | 2021-2023 | |
| Painteq LLC | $62.07 | 2024 | Painteq |
| Redhill Biopharma INC. | $61.78 | 2021-2023 | |
| Globus Medical, INC. | $57.50 | 2025 | Senza |
| Vertex Pharmaceuticals Incorporated | $38.28 | 2024-2025 | |
| Almatica Pharma LLC | $31.81 | 2021 | |
| Merz Pharmaceuticals, LLC | $28.19 | 2021 | |
| Lundbeck LLC | $22.40 | 2021 | |
| Indivior INC. | $21.66 | 2023 | Sublocade |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.07 | 2025 | Relistor |
| Electronic Waveform Lab, INC. | $18.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.16 | 2021 | |
| Biodelivery Sciences International, INC. | $17.12 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.67 | 2021 | |
| Allergan, INC. | $15.30 | 2022 | |
| Lilly USA, LLC | $14.96 | 2021 | |
| Averitas Pharma INC. | $13.61 | 2023 | Qutenza |
| Si-Bone, INC. | $12.30 | 2021 | |
| Forte Bio-Pharma LLC | $12.03 | 2021 | |
| Trevena, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Mallory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.